ArticleFuture oncology (London, England)2022

A phase II trial of the super-enhancer inhibitor Minnelide™ in advanced refractory adenosquamous carcinoma of the pancreas.

Nebojsa Skorupan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.